These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7883781)

  • 21. Inhibition of cell growth by combination of alpha-difluoromethylornithine and an inhibitor of spermine synthase.
    He Y; Shimogori T; Kashiwagi K; Shirahata A; Igarashi K
    J Biochem; 1995 Apr; 117(4):824-9. PubMed ID: 7592545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of difference between cytotoxicity, cell cycle and morphonuclear effects of polyamines on sensitive and multidrug resistant P388 cell lines.
    Berlaimont V; Pauwels O; Dubois J; Hanocq M
    Anticancer Res; 1997; 17(3C):2057-64. PubMed ID: 9216664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of smear preparation and fixatives on the DNA ploidy and the morphonuclear features of the MXT mammary tumor and normal tissues in the mouse.
    de Launoit Y; Kiss R; Danguy A
    Cytometry; 1990; 11(6):691-9. PubMed ID: 2200656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of hormono- and/or chemotherapy on the MXT mouse mammary tumor as monitored by 31P MRS.
    Scheiber C; Kiss R; De Launoit Y; Sijens P; Frühling J
    Eur J Cancer; 1990 Mar; 26(3):241-51. PubMed ID: 2141481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
    Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
    Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MXT mammary tumor treated by low dose chemotherapy. A 31P-NMR and 1H-MRI study.
    Scheiber C; Kiss R; De Launoit Y; Frühling J
    Anticancer Res; 1988; 8(3):403-7. PubMed ID: 2839100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Study of Pharmacological Properties of Doxorubicin-NPh.
    Nemtsova ER; Tikhonova EG; Bezborodova OA; Pankratov AA; Venediktova JB; Korotkevich EI; Kostryukova LV; Tereshkina JA
    Bull Exp Biol Med; 2020 Oct; 169(6):778-782. PubMed ID: 33123920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
    Ripamonti M; Pezzoni G; Pesenti E; Pastori A; Farao M; Bargiotti A; Suarato A; Spreafico F; Grandi M
    Br J Cancer; 1992 May; 65(5):703-7. PubMed ID: 1586598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo influence of androgens on the cell kinetics and chromatin pattern of the MXT mouse mammary tumor treated or not by aminoglutethimide.
    de Launoit Y; Kiss R
    J Cancer Res Clin Oncol; 1989; 115(2):129-38. PubMed ID: 2469677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antitumor effects of a new antitumor agent, zinostatin stimalamer (YM881)--effects on experimental tumors in vitro and in vivo].
    Numasaki Y; Takahashi K; Masuda E; Nohara C; Maeda H
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2289-94. PubMed ID: 1834021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen.
    Tejeda M; Gaál D; Csuka O; Ullrich A; Schwab R; Pap A; Horváth A; Kéri G
    Cancer Detect Prev; 2003; 27(2):155-62. PubMed ID: 12670528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.
    Zeisig R; Fichtner I; Arndt D; Jungmann S
    Anticancer Drugs; 1991 Aug; 2(4):411-7. PubMed ID: 1797199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-leukaemic action of RuCl2 (DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388/DDP subline.
    Coluccia M; Sava G; Loseto F; Nassi A; Boccarelli A; Giordano D; Alessio E; Mestroni G
    Eur J Cancer; 1993; 29A(13):1873-9. PubMed ID: 8260245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy-induced nuclear alterations of morphologic and genomic characteristics in a human colon cancer grafted onto nude mice.
    Jannot MC; Yeaton P; Pauwels O; DePrez C; Astruc J; Chazottes E; Kruczynski A; Kiss R
    Dis Colon Rectum; 1995 Aug; 38(8):853-65. PubMed ID: 7634980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computerized morphonuclear analyses of Feulgen-stained nuclei from 11 chemosensitive and from 11 chemoresistant neoplastic cell lines.
    Pauwels O; Kiss R
    Anal Cell Pathol; 1994 Oct; 7(3):235-50. PubMed ID: 7531485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
    Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
    Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination effects of etoposide with other antitumor drugs in vitro and in vivo].
    Nishikawa K; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3739-45. PubMed ID: 2596858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.